Compare Danaos Corporation (DAC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs Incyte Corporation — how do they compare? Danaos Corporation trades at $171 (market cap $3.10B), while Incyte Corporation trades at $112.75 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 7.4× Danaos Corporation's market cap, and Danaos Corporation pays a 2.35% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaos Corporation for 25 Days and Incyte Corporation for 33 Days on average.
| DAC | INCY | |
|---|---|---|
Market Cap | $3.10B | $22.85B |
Volume | 286,008 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $170.22 | $129.93 |
52-Week Low | $84.05 | $83.80 |
Typical Hold Time | 25 Days | 33 Days |
Enterprise Value | $3.08B | $18.35B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaos Corporation (DAC) trades at $164.48, down 0.88% on the day, with strong fundamental metrics including a low P/E of 5.57 and robust profitability margins. The stock shows a bullish technical trend, trading above key moving averages, with recent earnings consistently beating expectations. The company maintains strong cash flow generation and has declared multiple dividends, reflecting financial health and shareholder returns.
The outlook remains positive given DAC's undervaluation, earnings momentum, and dividend payments. Key risks include shipping industry cyclicality and global trade volatility. Analyst consensus is evenly split between Buy and Hold, indicating cautious optimism amid strong fundamentals and technical strength.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
